Shanghai Baxter Up For Grabs
This article was originally published in PharmAsia News
Executive Summary
Laden by bad bank debts, Shanghai Worldbest Treeful Pharmaceutical Group (SWTP) has put up for auction its 40-percent share of Shanghai Baxter, a joint venture with U.S. Baxter. Shanghai Baxter's core business of manufacturing and administration of intravenous products complements well with the key focus of rival Beijing Double-Crane Pharmaceutical (BDP)-the biggest intravenous product manufacturer in China-who went into a bidding war with U.S. Baxter at an auction on Jan. 25 for the shares. Baxter emerged the winner with its offer of 180 million yuan, five times higher than SWTP's $4.8 million initial payout for the shares. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.